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Development and validation of a prediction score for
postoperative acute renal failure following liver resection
Abstract
OBJECTIVE: To develop and validate a score to predict postoperative acute renal failure (ARF) after
liver resection. BACKGROUND: Postoperative ARF after major surgery is associated with morbidity
and mortality. Early identification of patients at risk of ARF is important in order to provide protective
kidney treatment. METHODS: Postoperative ARF was prospectively assessed in consecutive patients
undergoing liver resection. In randomly selected two-third of the total number of patients, multivariate
logistic regression analysis was used to develop a new prediction score (including a full and a reduced
model), based on the preoperative parameters of age, gender, preexisting chronic renal dysfunction,
cardiovascular disease, diabetes, bilirubin, and alanine aminotransferase (ALT) levels. In the remaining
last third of the patients, the new score was validated by calibrating the accuracy of the score
(ClinicalTrials.gov NCT 00743132). RESULTS: Postoperative ARF occurred in 15.1% (86 of 569
consecutive patients) from 2002 to 2007 and was highly associated with mortality (22.5% vs. 0.8%
without ARF, P < 0.001). In the 380 (two-third of the population) patients selected for the development
of the prediction score, preoperatively elevated ALT, preexisting cardiovascular disease, chronic renal
failure, and diabetes were the strongest predictors of ARF. Validating the full prediction model (0-22
points) to the remaining 189 patients (one-third of the population), the risk could be predicted accurately
(mean predicted risk of 11.5% vs. an observed risk of 14.8%) without significant differences between
predicted and observed risks across different risk categories (P = 0.98). Prediction with the reduced
model including the 4 strongest predictors (0-7 points) was almost as accurate as with the full model
(11.4% predicted vs. 14.8% observed) and also without significant differences across different risk
categories (P = 0.75). CONCLUSIONS: The new prediction score (the full as well as the reduced
model) accurately predicted postoperative ARF after liver resection. The use of these scores allows early
identification of patients at high risk of ARF, and may support decision making for protective kidney
interventions perioperatively.
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Abbreviations: Acute renal failure (ARF), alanine aminotransferase (ALT), risk injury 
failure loss (RIFLE), end stage renal disease (ESRD), standard deviation (SD), aspartate 
aminotransferase (AST), confidence interval (CI), intensive care unit (ICU), central venous 
pressure (CVP), middle arterial pressure (MAP), glomerular filtration rate (GFR), nitric 
oxide (NO), carbon monoxide (CO), chronic obstructive pulmonary disease (COPD).  
 
 
MINI ABSTRACT 
Postoperative acute renal failure (ARF) is associated with high morbidity and mortality. The 
new prediction score, including a full as well as a reduced model, accurately predicted ARF 
after liver resection. This score allows early identification of patients at high risk of ARF and 
may support decision-making for protective kidney interventions.  
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ABSTRACT  
Objective:  
To develop and validate a score to predict postoperative acute renal failure (ARF) after liver 
resection. 
 
Background:  
Postoperative ARF after major surgery is associated with morbidity and mortality. Early 
identification of patients at risk of ARF is important in order to provide protective kidney 
treatment.  
 
Methods:  
Postoperative ARF was prospectively assessed in consecutive patients undergoing liver 
resection. In randomly selected two third of the total number of patients, multivariate logistic 
regression analysis was used to develop a new prediction score (including a full and a reduced 
model), based on the preoperative parameters of age, gender, pre-existing chronic renal 
dysfunction, cardiovascular disease, diabetes, bilirubin and alanine aminotransferase (ALT) 
levels. In the remaining last third of the patients, the new score was validated by calibrating 
the accuracy of the score. (ClinicalTrials.gov NCT 00743132) 
 
Results:  
Postoperative ARF occurred in 15.1% (86 out of 569 consecutive patients) from 2002 to 2007 
and was highly associated with mortality (22.5% vs. 0.8% without ARF, p<0.001). In the 380 
(two third of the population) patients selected for the development of the prediction score, 
preoperatively elevated ALT, pre-existing cardiovascular disease, chronic renal failure and 
diabetes were the strongest predictors of ARF. Validating the full prediction model (0–22 
points) to the remaining 189 patients (one third of the population), the risk could be predicted 
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accurately (mean predicted risk of 11.5% versus an observed risk of 14.8%) without 
significant differences between predicted and observed risks across different risk categories 
(p=0.98). Prediction with the reduced model including the four strongest predictors (0-7 
points) was almost as accurate as with the full model (11.4% predicted versus 14.8% 
observed) and also without significant differences across different risk categories (p=0.75).  
 
Conclusions:  
The new prediction score (the full as well as the reduced model) accurately predicted 
postoperative ARF after liver resection. The use of these scores allows early identification of 
patients at high risk of ARF, and may support decision making for protective kidney 
interventions perioperatively. 
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  Acute renal failure (ARF) is a major complication after abdominal surgery, associated 
with substantial mortality, morbidity and costs.1-3 Reported incidences of postoperative ARF 
range from 1 % after major non-cardiac surgery without liver resection3 to around 20% after 
cardiac surgery4-6 and up to 50% after liver transplantation.7-13 The comparability of 
postoperative ARF across different studies is difficult due to a lack of standardized definition 
of ARF. Only very limited data exists regarding the occurrence of ARF in patients after liver 
resection, as well as its impact on outcome.14-17  
It is essential to identify, ideally preoperatively, those patients at risk to develop ARF 
to perform prevention strategies for this population. Effective preventive modalities involve 
all related disciplines including surgery, anesthesia and intensive care. Perioperative 
management to lower the risk of ARF could include fluid management, suspension of 
nephrotoxic drugs and protective strategies for ischemic reperfusion injuries.18-20 There is 
currently no validated prediction score available to identify patients undergoing liver 
resection at risk for postoperative ARF. Kheterpal S. et al developed a prediction score for 
ARF after non-cardiac surgery in patients with previous normal renal function3 but they failed 
to validate the score system. Proper validation is indispensable before the routine use in 
clinical practice of any predictive score system.21 Moreover few studies identified risk factors 
for postoperative ARF in cardiac22 and liver transplant patients, but without developing 
prediction rules.8, 11, 13 Therefore, the aim of this study was to develop and validate a simple 
and readily applicable score based on preoperative parameters to predict postoperative ARF in 
patients scheduled for liver resection. 
 
MATERIAL AND METHODS 
Study design, Population 
We conducted a cohort study and included consecutive patients undergoing any type of 
liver resection between July first, 2002 and October 31, 2007 in a single tertiary care center 
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(Swiss Hepato-Pancreato-Biliary Center, University Hospital of Zurich, Switzerland). Patients 
with trauma of the liver were excluded. All data were collected using standardized forms and 
entered into the database of the Swiss Hepato-Pancreato-Biliary Center. The study was 
approved by the institutional review board for human studies and internationally registered at 
clinicaltrials.gov (NCT 00743132).  
 
Perioperative management 
The perioperative management in our HPB centre was constant during the whole study 
period following modern guidelines in liver surgery. Intra- and early postoperative care was 
performed in a close collaboration of surgery with anesthesiology, intermediate and intensive 
care. unit to offer an optimized treatment after surgery. A special attention was given to the 
fluid management with policy of low volume and low central venous pressure 
intraoperatively.  
 
Definition of postoperative ARF 
 Postoperative ARF was defined according to the RIFLE criteria as an absolute 
increase in serum-creatinine of more than 0.3 mg/dl above baseline, or an increase of more 
than 1.5 times the preoperative baseline value within 48 hours after surgery, or a reduction of 
urinary output less than 0,5 ml/kg/h for at least 6 h.23-27A renal failure in context with a 
multiorgan failure occurring much later than 48 hours postoperatively was not defined as 
“postoperative ARF”. 
  
Selection of predictors of ARF 
In order to facilitate the future use and further validation of our prediction score, we 
only considered preoperative, reproducible, readily available predictive parameters. We also 
decided a priori to restrict the number of potential predictors to less than ten in order to 
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increase the applicability of the score in practice and to reduce the risk of over-fitting that 
would threaten the accuracy of the prediction score in other populations. 
Therefore, we considered the following predictors: age, gender, pre-existing chronic 
renal failure, cardiovascular disease, diabetes as well as preoperative bilirubin and alanine 
aminotransferase levels (ALT). We did not consider parameters like malignancy of liver 
disease, neoadjuvant chemotherapy, or whether patients had a primary and secondary liver 
tumor because they have not shown significant associations with ARF.17, 28-30 Since we 
considered only preoperative parameters in order to develop a risk score that support peri-
operative, decision-making for kidney-protective treatments, we excluded parameters that 
become available intra- or postoperatively (for example, histological features ).  
 Chronic renal failure was defined as a glomerular filtration rate of less than 60 
ml/min/1.73 m2 for all adults.31, 32 Cardiovascular disease was defined as the presence of a 
coronary heart disease, previous coronary revascularization, cerebral arterial occlusive disease 
and/or peripheral vascular occlusive disease.    
 
Statistical analysis  
We followed the standard approach to develop a prediction score.21, 33, 34 We first 
developed the multivariate model to predict ARF in a randomly selected two-thirds of our 
study population (so-called derivation population), and validated the model in the remaining 
third (validation population). For the random selection of patients for the derivation and 
validation population we specified that the incidence of ARF should be comparable in both 
populations (defined as the incidence for the entire population). For the development of the 
prediction score in the derivation population we developed a multivariate logistic regression 
model with ARF as the dependent and all seven predictors as independent variables. We 
calculated the area under the curve to estimate how well the model discriminated between 
patients with and without ARF. In order to reduce the risk that the multivariate logistic 
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regression model overestimated the associations of the seven predictors with ARF (impairing 
the accuracy of the model for other populations) we used shrinkage. Shrinkage describes the 
use of a constant factor (for example 0.8) with which the regression coefficients of the seven 
predictors are multiplied. The size of the shrinkage factor expresses the overoptimism of the 
multivariate model and depends on the goodness of fit of the multivariate logistic regression 
model and the number of predictors.35 
All prediction models must be validated in a new set of patients before use in practice21, 
33, 34 to ensure the predicted risks for an outcome provide an accurate and reliable basis for 
treatment decisions. The most important requirement for a prediction score is that the 
predicted risk for the outcome (for example a 20% risk of ARF in a specific patient) is as 
accurate as possible. For this purpose we assessed the calibration of our multivariate logistic 
regression model. Calibration refers to the comparison of risks as predicted by the model with 
the actual observed risks. We assessed calibration-in-the-large, which is the comparison 
between the mean predicted risk for ARF in our validation population and the observed risk 
of ARF (proportion of patients with postoperative ARF). In addition, we compared predicted 
and observed risks for ARF within different risk classes (> 0 - 10%, > 10 - 20%, etc) and used 
the Hosmer-Lemeshow test to assess whether predicted and observed risks differed 
significantly from each other, which would indicate poor calibration. 
Finally, we were interested in whether the inclusion of only the four strongest predictors 
instead of all predictors would still provide an accurate prediction model. Fewer variables 
would further increase the applicability of the prediction score in practice. To select the four 
strongest predictors we used a stepwise backward logistic regression model that retained 
variables with an association of p≤0.3.33 We used bootstrapping to repeat the selection process 
380 times (size of derivation population) and chose those four variables that were selected 
most often. Bootstrapping is a method to validate the selection of variables within the same 
data set. We then repeated all the above analyses and compared discrimination (area under the 
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curve) and calibration between the full model (seven predictors) and the reduced model (four 
predictors).  
Since the use of regression equations is hardly implementable in clinical practice we 
developed a simple prediction score from the underlying regression equations following a 
standard approach.36 Briefly, the regression coefficients are transformed into points so that 
they reflect the strengths of association. For example, for a predictor that is weakly associated 
with the outcome, only one point is assigned, whereas a strong predictor receives three or 
more points. The points for each predictor are summed up and for each total score a specific 
risk for ARF is given. The appendix table (Table 6) describes this transformation process in 
detail. We used R (version 2.4.1, R Foundation for Statistical Computing, Vienna, Austria) 
and STATA (version 10, Stata Corp., College Station, Texas) for the analyses. 
 
RESULTS 
Study population 
576 consecutive patients were assessed for eligibility in our department. After exclusion 
of seven trauma cases, 569 patients were finally included in the study (Figure 1). Mean age 
was 57.2 years (standard deviation [SD] 14.3), 12.8% had pre-existing chronic renal disease, 
74.9% suffered from malignant liver disease, of whom 49.3% received a preoperative 
chemotherapy (Table 1). Major liver resection was performed in 57.3% of patients, and the 
average duration of surgery was almost five hours (Table 2).  
 
 
Outcome following liver resection 
The incidence of postoperative ARF was 15.1% (86 out of 569 patients) and overall 
mortality 4.2% (24 out of 569 patients). Table 1 shows that patients with ARF were on 
average 10 years older (mean age 65.1 years [SD 11.3 years]) than patients without ARF 
(55.8 years [14.4 years]). Patients with ARF suffered more often from pre-existing 
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cardiovascular disease (29.1% vs. 8.9%), diabetes (22.1% vs. 8.3%), chronic obstructive 
pulmonary disease (10.5% vs. 5.4%) and chronic renal failure (32.6% vs. 9.3%). Preoperative 
ALT, aspartate aminotransferase (AST) and bilirubin levels were higher in patients with ARF. 
Also intraoperative parameters such as liver cirrhosis (Table 3, 11.6% vs. 6.2%), fibrosis 
(34.9% vs. 17.2%), advanced steatosis (17.5% vs. 10.6%) were more frequent and the rate of 
major liver resection (67.4% vs. 55.5%, respectively) as well as blood loss was higher (mean 
blood loss 768.1 mL [SD 714.7 mL]) vs. 508.0 mL [657.5 mL], respectively) in the ARF 
group compared with the non ARF group. Patients with ARF were significantly more likely to 
die within 30 days (23.2%) compared to patients without ARF (0.8%, unadjusted odds ratio 
36.3 [95% CI: 12.0 – 109.9], p<0.001) and odds ratio 22.5 [95% CI 6.2 – 81.7], p<0.001, 
when adjusted for age, gender, pre-existing cardiovascular diseases, chronic obstructive 
pulmonary disease, diabetes, chronic renal failure, peak ALT and malignancy of liver 
disease). Also, length of ICU (adjusted difference 7.9 days [95% CI 6.4 – 9.3], p<0.001) and 
hospital stay (adjusted difference 9.5 days [95% CI 6.7 – 12.4], p<0.001) were also 
statistically significantly longer in patients with postoperative ARF compared to patients 
without ARF (Table 3). Table 4 shows the outcome in patients with or without postoperativ 
renal failure including the cause of death. The progress of the postoperative ARF is 
demonstrated in Table 5. In 26.7% of the patients with acute renal failure a postoperative 
hemofiltration had to be performed and 5 out of those 23 patients (21.7%) needed a persistent 
hemodialysis.    
 
Development of the prediction model 
Of the 380 patients (two thirds) randomly selected for the development of the prediction 
model, 58 (15.3%) had postoperative ARF (Figure 2). Table 6 shows the multivariate model 
with the seven predictors of ARF and the risk score. Elevated ALT levels (> 35/50 U/L for 
women/men, respectively), showed the greatest association with postoperative ARF (odds 
Slankamenac K, Breitenstein S et al.          Version 19 August 2009, Vers 1                                           9
ratio 3.34) followed by pre-existing cardiovascular disease (odds ratio 3.29), pre-existing 
chronic renal failure (3.08) and diabetes (2.34). The area under the curve was 0.80, which 
indicated good discrimination of patients with and without ARF by the combination of the 
seven predictors. The point score ranges from 0 to 22 points (highest risk for ARF). For the 
four strongest predictors, 3 to 5 points are assigned when present, whereas for elevated 
bilirubin levels (≥ 17 µmol/l) and female gender only 1 point is assigned. 
 
Validation of the prediction model 
The validation population comprised the remaining 189 patients (Figure 2). Based on 
the multivariate model, the predicted mean risk for ARF was 11.5%, while the observed risk 
for ARF was 14.8% (28 out of 189 patients). Thus, the overall predicted risk differed from the 
observed risk by only 3.3%. Predicted and observed were very similar across the entire range 
of risk for ARF, which was confirmed by the Hosmer-Lemeshow test (p=0.98) for differences 
between predicted and observed risks across risk classes. 
 
Development and validation of the reduced prediction model 
We selected pre-existing cardiovascular disease, elevated ALT levels (> 35/50 U/L for 
women/men, respectively), pre-existing chronic renal failure and diabetes for the reduced 
prediction model because they were selected most often as important predictors of ARF in the 
380 repetitions of the backward logistic regression selection process (358 times for pre-
existing cardiovascular disease, 350 times for pre-existing chronic renal failure, 339 times for 
diabetes and 300 times for high ALT levels). Table 7 shows the development of the regression 
model and the prediction score. The area under the curve was 0.77, which was only slightly 
less than for the seven predictors. The point score ranges from 0 to 7 points (highest risk for 
ARF). 
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The mean predicted risk was 11.4%, which was 3.4% below the observed risk (14.8%). 
The Hosmer-Lemeshow test confirmed that predicted and observed risks did not differ 
significantly across risk classes (p=0.75). Calibration of the reduced risk model was therefore 
nearly as good as for the full model with seven predictors.   
 
Full and reduced risk score to predict ARF after liver resection 
Tables 6 and 7 show how many points are assigned if a risk factor is present. Finally, 
Table 8 shows the risk of ARF associated with each point increase for the full and reduced 
risk score. For example, using the full score, a score of 7 is associated with a risk of 17.8%. 
The full score provides a wide range of risk prediction from 4.1% for 0 points to 87.3% for 22 
points and a subtle differentiation of the risk for ARF. In turn, the reduced risk score ranges 
from 5.8% to 80.5% with larger intervals between risk scores.  
 
Discussion 
We developed and validated an easily applicable score to predict the risk for ARF in 
patients scheduled for liver resection. Early identification of patients at high risk of ARF is 
important because, as our study showed, ARF is strongly associated with mortality and the 
need for extended ICU and hospital care. The score based on seven parameters showed good 
discrimination and calibration. We also developed a reduced score based on the four strongest 
predictors such as pre-existing cardiovascular disease, chronic renal failure, diabetes and high 
levels of ALT, which predicted ARF nearly as accurately as the full score. Depending on the 
purpose, clinicians and investigators can choose between the full and the reduced risk score. 
While the full score provides a more subtle prediction of the risk for ARF, the reduced score 
is simpler, and more likely to be used in clinical practice.   
 Postoperative acute renal failure is known to significantly impair the outcome after 
major surgery.1, 3 However, the lack of a standard definition of postoperative ARF has 
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hindered the comparability of published data.23-27 Neither the incidence nor the clinical 
relevance (mortality, morbidity and hospital stay) of postoperative ARF following liver 
surgery have been conclusively clarified. To our knowledge, the present study represents the 
largest series of patients focused on the evaluation of postoperative ARF following liver 
resection in a modern specialized center, and over a recent period of time. Acute renal failure 
was defined according the so called RIFLE criteria representing the internationally most 
accepted and validated criteria based on interdisciplinary, international consensus process 
carried out by ADQI (Acute Dialysis Quality Initiative)-Workgroup23-25, 27 Postoperative ARF 
was documented in 15.1 % of the patients following liver resection, and significantly 
correlated not only with an increased mortality compared to patients without postoperative 
ARF (23.2% versus 0.8%, p<0.001), but also with a prolonged length of hospital (adjusted 
difference 9.5 days [95% CI 6.7 – 12.4], p<0.001) and ICU (adjusted difference 7.9 days 
[95% CI 6.4 – 9.3], p<0.001) stay. Acute renal failure was the main reason for death in more 
than half of the patients (12) who died, while the second most cause of death was infection 
(Table 4).  
A validated score as this one is of importance. From an academic perspective, it is a tool 
to stratify the risks of patient collectives within scientific projects. Moreover, it may directly 
impacts on future clinical practice. Risk scores combine information available at a moment 
where decisions might be taken and our score aims at a preoperative evaluation of the 
postoperative risk for ARF. This is of particular importance because kidney function can be 
influenced by several modifiable factors in the interdisciplinary perioperative management 
process (surgery, anesthesiology and intensive care medicine). Therefore, the present score 
may support decision-making for kidney-protective interventions during the entire 
perioperative period, which may improve patient outcomes. Of note, intraoperative 
parameters including histological features such as steatosis or blood loss can still be 
considered to update the pre-operative risk prediction and to support decision-making for the 
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post-operative management. For example, a patient might be at moderate risk pre-operatively 
but have a much higher risk for ARF after suffering from substantial loss or after diagnosing 
severe steatosis. Such an updated risk score, however, would again need to be developed and 
validated.  
Therapeutic options to prevent and to treat ARF following liver resection include pre, 
intra- as well as postoperative approaches. There are several possible targets for optimizing, 
treating and influencing the postoperative renal function following liver resection as we will 
show in following passages.  
A number of preoperative predictors have been identified in this present study. It is 
obvious that treatable and modifiable parameters such as cardiac dysfunction, preoperative 
kidney dysfunction, diabetes and preoperative cholestasis should be optimized. Regarding 
intraoperative factors influencing the postoperative renal function, many parameters have 
been described. 16, 17, 28, 37-39 Blood loss and the extent of liver resection have been described 
as the most relevant risk factor for mortality and morbidity after hepatectomy.17, 28 In this 
context, the role of low intraoperative central venous pressure (CVP) and fluid restriction, 
which is a modern and widely accepted strategy in many hepato-biliary centers may need to 
be adjusted according to the risk of developing postoperative renal failure.16, 37, 38 Several 
studies have confirmed a reduced blood loss due to a low CVP (< 5 mmHg).16, 37, 38 Of these, 
Mendelez JA. et al.16 demonstrated a rate of acute renal failure of only 3.1%, while others 37, 
38 showed higher rates of postoperative renal failure, dialysis requirement and mortality with 
“too” low intraoperative CVP. This impairment of postoperative renal function may be caused 
more by an additional low arterial blood pressure than by the low intraoperative CVP itself as 
demonstrated by Abuelo JG. et al.39 Kidneys can maintain their blood flow in the mean 
arterial pressure (MAP) range between 80 and 120 mmHg. If the MAP falls to less than 80 
mmHg, there is a significant drop in the glomerular filtration rate (GFR) and the risk of 
developing an ARF increases. Further scientific investigations are required regarding the 
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impact of intraoperative parameters such as blood loss, CVP, and MAP on postoperative ARF 
particularly in relation to the present risk score.   
 Postoperative liver failure after hepatic resection changes the hemodynamics similar to 
those of patients with cirrhosis or acute liver failure14, 40 implicating a severe risk of renal 
failure. Increased risk for postoperative liver failure has been considered in patients with 
major liver resection with a consecutive small remnant liver volume, advanced age, steatosis 
and cirrhosis.41-44 Postoperative liver failure is a hyperdynamic state with increased cardiac 
output. It is caused by a largely increased concentration of nitric oxide (NO) in the 
circulation, as shown in both animal and clinical trials.45, 46 As a result, a severe vasodilation 
of the splanchnic area leads to a declining central and arterial blood volume, low pulmonary 
capillary wedge pressure, low CVP, low systemic vascular resistance, increased carbon 
monoxide (CO) and reduced MAP. If the MAP drops below 80 mmHg, the GFR will 
significantly decrease.47 Based on this, similar to the mechanism of “hepatorenal 
syndrome”48, intravascular hypovolemia activates the renin-angiotensin-aldosterone system 
and sympathetic nervous system. A subsequent vasoconstriction within the kidney lowers 
GFR, causing necrosis and apoptosis of tubular cells, which are sloughed, obstructing the 
lumen; finally, the GFR completely deteriorates.39 Although some correlation exists between 
postoperative liver and kidney insufficiency, risk factors and also potential preventive 
strategies are different. Liver insufficiency is another endpoint which needs to be evaluated 
with a separate prediction model. Therefore, the outcome factor liver insufficiency was not 
evaluated in detail in the present study.  
Before our scores are used widely, it is important that they are validated in other 
populations. It might well be that the score needs to be updated in populations where the 
incidence of ARF is higher or lower as it has been done for widely used risk scores such as 
the Framingham risk score. Also, future studies should compare the predictive performance of 
the full and the reduced risk scores in order to evaluate whether the reduced score can be used 
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safely without much loss on information. We will certainly provide any information necessary 
for such out-of-population validations. Further investigations are required to evaluate the 
impact of possible pre-, intra- and postoperative targets for optimizing, treating and 
influencing the postoperative renal function following liver resection, and to prevent an ARF 
following liver surgery. It would be attractive to consider intraoperative parameters (including 
histological features) to update the risk prediction in future models  
 Strengths of this study include the large sample size, which allowed us to develop and 
validate a risk score. Validation, i.e. the assessment of how close predicted risks are to 
observed risks (calibration), is indispensable before a risk score is used in practice. Another 
strength is the use of advanced statistical techniques such as shrinkage and bootstrapping that 
increase the validity and applicability of a prediction score in other settings. A limitation of 
this study is the fact that the patient cohort originated from one single center. We therefore 
encourage other groups to further validate the risk score in their population. This is very 
important to further assess the validity of the present score. 
 In conclusion we have developed a validated risk score to accurately predict ARF in 
patients scheduled for liver resection. The reduced model of the score based on the four 
strongest predictors is particularly attractive for clinical practice, whereas the full score based 
on seven parameters allows for a more subtle risk stratification. The use of this score allows 
early identification of patients at high risk of ARF and may support decision-making for 
kidney-protective interventions before, during and after liver resection. Prevention of ARF is 
important because our study has also showed that it is directly associated with mortality and 
the need for extended ICU and hospital care. 
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TABLES   
 
  
Table 1: Preoperative characteristics 
 All 
patients 
n = 569 
Postoperative 
non-ARF° 
n = 483 
Postoperative 
ARF° 
n = 86 
 
Age, mean ± SD† 
Age, median (range)   
Gender, male / female,  
                number (%) 
Body mass index (kg/m²), mean ± SD†  
Cardiovascular disease¹, number (%) 
Chronic renal failure, number (%) 
COPD², number (%)   
Diabetes, number (%) 
Viral Hepatitis, number (%)   
Charlson-Index 49, mean ± SD†  
Benign / Malignant disease,  
                number (%)                                
Primary / Secondary liver tumor,  
                number (%) 
Preoperative chemotherapy, number (%) 
Bilirubin (μmol/l), mean ± SD† 
AST ³ (U/l), mean ± SD† 
ALT * (U/l), mean ± SD† 
 
57.2 ± 14.3 
59 (13 – 90) 
311 / 258 
54.7% / 45.3% 
27.0 ± 32.3 
68 (12.0%) 
73 (12.8%) 
35 (6.2%) 
59 (10.4%) 
41 (7.2%) 
5.1 ± 3.6 
143 / 426 
25.1% / 74.9% 
280 / 267 
49.2% / 46.9% 
210 (36.9%) 
18.0 ± 34.7 
46.9 ± 71.9 
55.5 ± 78.5 
 
55.8 ± 14.4  
58 (13 – 90) 
265 / 218 
54.9% / 45.1% 
25.9 ± 4.8  
43 (8.9%) 
45 (9.3%) 
26 (5.4%) 
40 (8.3%) 
29 (6.0%) 
5.0 ± 3.7  
130 / 353 
26.92% / 73.%  
233 / 233  
48.2% / 48.2% 
187 (38.7%) 
16.7 ± 30.6 
45.3 ± 74.3 
53.3 ± 71.2 
 
65.1 ± 11.3 
67 (30 – 86) 
46 / 40 
53.5% / 46.5% 
25.0 ± 4.5 
25 (29.1%) 
28 (32.6%) 
9 (10.5%) 
19 (22.1%) 
12 (13.9%) 
5.8 ± 3.1 
13 / 73 
15.1% / 84.9% 
47 / 34 
54.7% / 39.5% 
23 (26.7%) 
25.2 ± 51.2 
55.5 ± 56.3 
67.7 ± 110.3 
 ¹ Cardiovascular disease is defined as coronary heart disease, previous coronary revascularization, cerebral arterial 
occlusive disease, peripheral vascular occlusive disease 
² COPD is defined as chronic obstructive pulmonary disease 
49 Charslon-Index is the most widely accepted and validated method, used to quantify comorbidities49 
³ AST = Aspartate-aminotransferase  
*ALT = Alanin-aminotransferase  
† SD = Standard deviation 
° ARF = Acute renal failure 
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Table 2: Intraoperative parameters 
 
 All 
patients 
n = 569 
Postoperative 
non-ARF° 
n = 483 
Postoperative 
ARF° 
n = 86 
 
Surgery time (minutes), mean ± SD†  
Major¹ / Minor² liver resection  
                number (%) 
Total inflow occlusion, number (%) 
Pringle time³ (minutes), mean ± SD† 
Blood loss (ml), mean ± SD† 
Blood transfusion, median (range) 
Cirrhosis, number (%) 
Steatosis  
    - total, number (%) 
    - < 30%, number (%) 
    - 30 – 60 %, number (%) 
    - > 60 %, number (%) 
    - unknown, number (%)   
Fibrosis, number (%)  
Single shot antibiotics 
    - aminoglycoside / 
      cephalosporin, number (%) 
    - others, number (%) 
    - unknown, number (%) 
 
294.2 ± 122.8 
326 / 243 
57.3% / 42.7% 
208 (36.6%) 
31.7 ± 11.1 
551.0 ± 673.4 
1 (0 – 18) 
40 (7.0%) 
 
190 (33.4%) 
  121 (21.3%) 
 36 ( 6.3%) 
 30 (5.3%) 
  3 (0.5%) 
  113 (19.9%) 
 
 
447 (78.6%) 
27 ( 4.7%) 
85 (14.9%) 
 
285.1 ± 113.1 
268 / 215 
55.5% / 44.5% 
171 (35.4%) 
31.7 ± 10.8 
508.0 ± 657.5 
1 (0 – 18) 
30 (6.2%) 
 
149 (30.9%) 
  96 (19.9%) 
 25 ( 5.2%) 
 26 ( 5.4%) 
  2 ( 0.4%) 
  83 (17.2%) 
 
 
383 (79.3%) 
17 ( 3.5%) 
73 (15.1%) 
 
340.6 ± 156.9 
58 / 28  
67.4% / 32.6% 
37 (43.0%) 
31.7 ± 12.6 
768.1 ± 714.7 
1 (0 – 15) 
10 (11.6%) 
 
41 (47.7%) 
25 (29.1%) 
11 (12.8%) 
4 ( 4.7%) 
1 ( 1.2%) 
30 (34.9%) 
 
 
64 (74.4%) 
10 (11.6%) 
12 (13.9%) 
 ¹ Major liver resection is defined as a resection of at least 3 Couinaud’s liver segments 
² Minor liver resection is defined as a resection of less than 3 Couinaud’s liver segments  
³ Pringle time = Total inflow occlusion 
† SD = Standard deviation 
° ARF = Acute renal failure 
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Table 3: Association of renal dysfunction with clinical outcomes  
 
 
Group 
 
Outcome 
 
Median (IQR) 
 
Raw difference 
(95% CI) 
 
Adjusted difference 
(95% CI) 
 
Renal dysfunction ¹ 
No renal dysfunction ² 
 
Renal dysfunction ¹ 
No renal dysfunction ²  
 
Hospital stay in days 
 
 
 
 
 
ICU stay in days 
 
18 (12 – 31) 
11 (  9 – 16) 
 
5 (  1 – 10) 
1 ( 0  –   1) 
9.75 
(7.11 – 12.38, p < 0.001) 
 
7.79 
(6.45  - 9.13, p < 0.001) 
9.5 
(6.65 – 12.36, p < 0.001) 
 
7.89 
(6.43 – 9.34, p < 0.001) 
¹ n = 86 
² n = 483 
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Table 4: Postoperative Outcome  
 
 
 All 
patients 
n = 569 
Postoperative 
non-ARF° 
n = 483 
Postoperative 
ARF° 
n = 86 
 
Overall morbidity  
No postoperative complications  
 
Overall mortality  
 
Mortality based on 
-     Acute renal failure  
-     Intra-abdominal infection 
-     Liver insufficiency  
-     Cardiac insufficiency 
-     Sepsis, unknown focus  
 
295 (51.8%) 
274 (48.2%) 
 
24 (4.2%) 
 
 
12 (2.1%) 
4 (0.7%) 
3 (0.5% 
3 (0.5%) 
2 (0.4%) 
 
220 (45.5%) 
263 (54.5%) 
 
4 (0.8%) 
 
 
0% 
0% 
3 (0.6%) 
1 (0.2%) 
0% 
 
75 (87.2%) 
11 (12.8%) 
 
20 (23.2%) 
 
 
12 (13.9%) 
4 (4.7%) 
0% 
2 (2.3%) 
2 (2.3%) 
 
° ARF = Acute renal failure 
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Table 5: Progress of postoperative renal failure  
 
 
 Overall 
n = 86  
(100%) 
 
Postoperative 
hemofiltration 
n = 23 
(26.7%) 
Postoperative 
no hemofiltration 
n = 63  
(73.3%) 
 
 
Preoperative normal renal function, number (%)   
Pre-existing chronic renal failure, number (%) 
Recovery of renal dysfunction, number (%) 
Postoperative persistent haemodialysis (HD), number (%)  
Postoperative chronic renal failure without HD, number (%) 
Mortality, number (%) 
 
58 (67.4%) 
28 (32.6%) 
20 (23.3%) 
5 (5.8%) 
41 (47.7%) 
20 (23.3%) 
 
20 (87.0%) 
3 (13.0%) 
2 (8.7%) 
5 (21.7%) 
2 (8.7%) 
14 (60.9%) 
 
38 (60.3%) 
25 (39.7%) 
18 (28.6%) 
0 (0%) 
39 (61.9%) 
6 (9.5%) 
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Table 6: Development of predictor score based on multivariate logistic regression model 
 
Predictor 
 
Categories Regression 
coefficient β # 
Odds ratio (β) p-value Shrinked 
coefficient βs* 
Shrinked odds 
ratio (βs) 
Risk scoreº 
Cardiovascular disease 
 
no 
yes 
 
1.19 
 
3.29 
 
0.004 
 
1.02 
 
2.78 
0 
5 
Chronic renal failure 
 
no 
yes 
 
1.13 
 
3.08 
 
0.003 
 
0.98 
 
2.63 
0 
4 
Diabetes 
 
no 
yes 
 
0.85 
 
2.34 
 
0.045 
 
0.73 
 
2.07 
0 
3 
ALT 
 
≤ 35/50 U/l§ 
>35/50 U/l§ 
 
1.21 
 
3.34 
 
0.001 
 
1.03 
 
2.82 
0 
5 
Age 
 
<60 years 
60 – 69 years 
≥ 70 years 
 
0.29 
0.62 
 
1.34 
1.86 
 
0.456 
0.146 
 
0.25 
0.53 
 
1.29 
1.70 
0 
1 
3 
Bilirubin 
 
< 17 μmol/l 
≥ 17 μmol/l 
 
0.23 
 
1.26 
 
0.521 
 
0.20 
 
1.22 
0 
1 
Female  no 
yes 
 
0.27 
 
1.31 
 
0.412 
 
0.23 
 
1.26 
0 
1 
# Compared with reference category, which is no cardiovascular disease, no chronic renal failure, no diabetes, ALT ≤ 35/50 U/l for women/men, age < 60 years, bilirubin < 17 μmol/l and male 
gender, respectively. Constant = -3.297 
§ cut-offs for women/men 
*Shrinkage coefficient: 0.86 
° 1 point is assigned per 10 years increase of age = coefficient of 0.25 (reference category). Points rounded to the next integer. 
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Table 7: Development of reduced predictor score based on multivariate logistic regression model 
 
Predictor 
 
Categories Regression 
coefficient β 
Odds ratio (β) p-value Shrinked 
coefficient βs 
Odds ratio (βs) βs* category  Risk score° 
Cardiovascular Disease 
 
no 
yes 
 
1.331 
 
3.783 
 
0.001 
 
1.236 
 
2.974 
0 
1.236 
0 
2 
Chronic renal failure 
 
no 
yes 
 
1.329 
 
3.777 
 
0.0001 
 
1.235 
 
2.970 
0 
1.235 
0 
2 
Diabetes 
 
no 
yes 
 
0.855 
 
2.352 
 
0.036 
 
0.794 
 
2.015 
0 
0.794 
0 
1 
ALT 
 
≤ 35/50 U/l§ 
>35/50 U/l§ 
 
1.336 
 
3.805 
 
0.0001 
 
1.241 
 
2.988 
0 
1.241 
0 
2 
# Compared with reference category, which is no cardiovascular disease, no chronic renal failure, no diabetes and ALT < 35/50 U/l§, respectively 
§ cut-offs for women/men 
*Shrinkage coefficient: 0.929 
°1 point is assigned for a coefficient of 0.794 (reference category = ALT > 35/50 U/l§). Points rounded to the next integer. 
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Table 8: Prediction of risk of ARF using the full and the reduced prediction score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Full risk 
score 
(7 predictors) 
Risk of 
ARF 
 Reduced risk 
score 
(4 predictors) 
Risk of 
ARF 
0 4.1%  0 5.8% 
1 5.2%  1 10.1% 
2 6.4%  2 17.0% 
3 7.9%  3 27.2% 
4 9.8%  4 40.5% 
5 12.0%  5 55.3% 
6 14.7%  6 69.3% 
7 17.8%  7 80.5% 
8 21.4%  
9 25.6%  
10 30.2%  
11 35.3%  
12 40.7%  
13 46.4%  
14 52.1%  
15 57.8%  
16 63.3%  
17 68.5%  
18 73.2%  
19 77.5%  
20 81.3%  
21 84.5%  
22 87.3%  
  
Example for reduced risk score: Patient without pre-existing cardiovascular disease (0 point), 
with chronic renal failure (2 points), diabetes (1 point) and ALT = 60 U/l (2 points)  total of 
5 points = risk of ARF of 55.3%. 
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Figure 1: Study population 
 
 
576 eligible patients
569 included patiens
483 patients without 
acute renal failure
86 patients with acute 
renal failure
Exclusion of 7 trauma 
patients
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Figure 2: Principle of the development and validation of the prediction score 
 
569 included patiens
Derivation population: 
380 patients
Validation population: 
189 patients
67% 33%Random
selection
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
